Junhem Biopharma Secures Nearly RMB 350 Million in Series B and B+ Financing to Advance Recombinant Protein Pipeline

VCBeat has learned that, recently,JHM Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as “JHM”) has secured over RMB 200 million in Series B+ financing, just three months after raising RMB 100 million in Series B funding from the listed company Tonghua Dongbao in late May this year. This brings JHM’s total fundraising to nearly RMB 350 million. The Series B+ round was led by SDIC Chuanghe, with participation from Ariose Capital, Oriza Holdings, and New Oxygen Group. WinX Capital served as the exclusive financial advisor across multiple consecutive rounds.The funds raised in this round of financing will be primarily used to further advance the development of the company’s product pipeline, deepen its presence in both serious healthcare and consumer healthcare sectors, and accelerate the industrialization and commercial promotion of its product portfolio.

Within just three months, the continuous support from market-oriented investors and industrial strategic partners has not only fully demonstrated the capital market’s high recognition of JHM Biopharma’s team and technology, but also provided the company with comprehensive resource allocation and empowerment spanning R&D, manufacturing, product registration, and market promotion, thereby driving rapid corporate growth.

JHM Biopharma, established in November 2020, is a biotechnology company dedicated to the development of innovative recombinant protein therapeutics and synthetic biology products. Leveraging years of expertise in the research, development, and industrialization of recombinant protein drugs, the company has accumulated core technologies, platforms, and talent covering the entire product development lifecycle, thereby establishing a comprehensive technical and product development system. Its R&D pipeline focuses on frontier protein drug sectors with broad market potential, including serious healthcare, consumer healthcare, and metabolism. JHM Biopharma has achieved large-scale manufacturing of high-end recombinant protein products, such as bulk solutions and formulations of recombinant human collagen types I and III, as well as recombinant botulinum toxin type A. Its technological capabilities and industrialization progress are at an internationally leading level.

Upon completion of this financing round, JHM Biopharma will continue to actively advance the R&D and clinical development of its core product pipeline, deepen its practical applications in both serious healthcare and consumer healthcare sectors, and continuously enrich its end-product portfolio in response to market demands, thereby accelerating the company’s entry into the commercialization phase.

Xu Kui, CEO of JHM BiopharmaStatement: We extend our sincere gratitude to all investors for their recognition and support of the company, and thank WinX Capital for its continued partnership and the team’s professional, efficient services, which facilitated the rapid completion of this financing round. The consumer healthcare and serious medical sectors hold immense market potential. JHM Biopharma remains committed to being market-demand-driven and innovation-led, focusing on the iterative development of underlying technologies while building a portfolio of technology platforms and product pipelines with independent intellectual property rights. Moving forward, we will continue to accelerate the progress of our R&D pipeline. We are confident that, through the joint efforts of our team and institutional investors, the company will emerge as a leader in the field of recombinant protein therapeutics.

Ariose CapitalStatement: The investment in JHM Biopharma signifies Ariose Capital’s determination to establish a presence in the hybrid sector of consumer and serious healthcare, as well as in synthetic biology. We also hold strong confidence in the JHM Biopharma team’s proven track record in the commercialization of recombinant protein drugs, and we are honored to partner with the team to support the company’s long-term development.

Oriza HoldingsStatement: We are optimistic about the significant growth potential in the consumer healthcare sector. The JHM Biopharma team possesses extensive industrialization experience and exceptional execution capabilities in the field of recombinant proteins, having efficiently resolved industrialization bottlenecks and cost issues for multiple pipelines, including recombinant botulinum toxin and recombinant collagen, within a short period. We are delighted to participate in the company’s development and look forward to the early market launch of its products to benefit a broad base of patients and users.

New Oxygen GroupStatement: The JHM Biopharma team boasts nearly two decades of industry experience, a high level of professionalism, and a spirit of continuous innovation. Having overcome technical barriers across multiple product pipelines, the team has established unique competitive advantages. We are confident that it will develop more products with international competitiveness in the future. SoYoung Group is pleased to continue investing in JHM Biopharma alongside its existing and new shareholders. We will provide multi-dimensional support and empowerment to help the company grow into an internationally renowned enterprise in the field of recombinant protein therapeutics.

WinX CapitalWinX Capital is honored to serve as JHM Biopharma’s long-term capital partner and to continue leading its subsequent financing rounds. We sincerely appreciate the trust placed in WinX Capital by both the company and its investors. As an active participant in the high-growth sector of recombinant protein therapeutics, JHM Biopharma boasts a deeply experienced team, industry-leading innovative platform technologies, strong product iteration capabilities, and extensive industrialization expertise. The company focuses on the substantial markets of serious healthcare and consumer health, with a rich pipeline of products closely aligned with market demands. We are confident that, with the support of its shareholders, JHM Biopharma will grow into an industry-leading recombinant protein therapeutics company, bringing benefits to a broad base of patients and consumers.

Ariose Capital specializes in equity investments within the healthcare and medical sector. Its limited partners include more than ten publicly listed healthcare companies, state-owned enterprises, market-oriented fund-of-funds, and local governments. The management team comprises industry leaders from Fortune 500 central pharmaceutical state-owned enterprises and top-tier private equity funds, with the core team boasting over 20 years of operational experience in the healthcare industry and more than 10 years of expertise in equity investment and management. Distinguished by its “ecosystem investment strategy” and “comprehensive post-investment empowerment,” Ariose Capital leverages the advantageous resources of listed industrial companies and its team to build a medical ecosystem. It conducts deep investment layouts closely aligned with ecosystem resources and fully utilizes these resources to provide value-added post-investment services to portfolio companies, thereby facilitating their growth and delivering superior returns to the fund’s investors.

Suzhou Oriza Holdings Corporation is a state-owned investment enterprise controlled by the state-owned assets of Suzhou Industrial Park and participated in by the provincial state-owned assets of Jiangsu Province. Since its establishment in 2001, the company has focused on investing in innovative enterprises, providing services for the science and technology innovation industry, attracting and nurturing scientific and technological talents, and integrating technology with finance. Adhering to national missions and government guidance, as well as market-oriented, professional, and international principles, it has grown into a first-class equity investment institution in China. The company deeply cultivates the field of equity investment, with the mission of serving the real economy and promoting industrial upgrading. It insists on investing early, investing in small businesses, investing for the long term, and investing in hard technology, striving to achieve the preservation and appreciation of state-owned assets and the coordinated development of regional industries. Investments in strategic emerging industry projects account for 95%, covering industries such as integrated circuits, biomedicine, and high-end manufacturing, spanning the entire life cycle of technology enterprises.

New Oxygen is a leading internet group in China, founded in 2013 with the mission of enabling 100 million Chinese people to access high-quality, affordable health and wellness services. To date, its platform covers 348 cities across China, attracting over 57,464 certified institutions and more than 30,000 doctors, with cumulative downloads exceeding 210 million. The Group maintains offices in more than ten domestic cities, including Beijing, Shanghai, Guangzhou, and Chongqing, as well as in South Korea, and employs over 1,000 staff members.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including being ranked No. 1 Financial Advisor in the Healthcare Sector for 2022 and 2023 by First New Voice; Top 2 Best Financial Advisor in the Healthcare Sector for 2021–2022 by Qimingpian & New Voice Innovation Services; and Annual Healthcare Financial Advisor at VCBeat’s “Top 100 Future Healthcare Companies” from 2022 to 2024.